Navigation Links
New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association's Scientific Sessions
Date:11/11/2010

dabigatran exposure and should generally be avoided. P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin, do not require dose adjustments. These results should not be extrapolated to other P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events. PRADAXA 150 mg resulted in a higher rate of major gastrointestinal (GI) bleeds and any GI bleeds compared to warfarin. In patients greater than or equal to 75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions.  These were commonly dyspepsia (including abdominal pain, upper abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, gastritis, and GI ulcer).  Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.  

For full PRADAXA prescribing information, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 188
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, Inc. ... a strategic collaboration to discover and develop antisense ... new collaboration builds on a broad existing relationship ... approach in these therapeutic areas using novel RNA-targeted ... use of its antisense technology to diseases of ...
(Date:7/31/2015)... N.C. , July 31, 2015  In today,s ... customers who are increasingly mobile, increasingly connected, and increasingly ... growing variety of customer interaction channels and tools is ... including social media. According to research ... over the counter (OTC) segment in a call center ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
... Wash., Oct. 21, 2011 Evergreen Healthcare today announced ... Care Excellence Awards for 2012 from HealthGrades, placing it ... its superior patient outcomes and significantly reduced mortality rates ... the third consecutive year, Evergreen was honored with HealthGrades, ...
... Fla., Oct. 21, 2011 Boca Pharmacal, Inc., today announced ... Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 ... 1 mg and Robinul Forte Tablets, 2 mg, distributed by ... adjunctive therapy in the treatment of peptic ulcers. ...
Cached Medicine Technology:Evergreen Named One of America's 100 Best Hospitals for Stroke Care 2Evergreen Named One of America's 100 Best Hospitals for Stroke Care 3Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets 2
(Date:8/3/2015)... NC (PRWEB) , ... August 03, 2015 , ... The ... by experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was ... Zereshki has decided to share her cookbook Recipes from My Persian Kitchen with the ...
(Date:8/3/2015)... Asbury Park, NJ (PRWEB) , ... August 03, ... ... is pleased to announce the development of it’s new program “Designing Secure Healthcare ... provide software architects, engineers and technology leaders from healthcare organizations with access to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... A July ... among U.S. emergency rooms in recent years, according to the American Dental Association. According ... of dental emergency visits went from 1.1 million in a single year to 2.2 ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... Miami, Florida (PRWEB) , ... August 03, 2015 , ... ... neuropathy pain accompanied by tissue injury caused by diabetes after many years of suffering ... work many times, and he didn’t want to ask for extra time off or ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3
... June 9 Par Pharmaceutical Companies, Inc. (NYSE: ... spray to the trade. Calcitonin-salmon nasal spray is a ... sales of Miacalcin were approximately $112 million in 2008, according ... Important information about calcitonin-salmon nasal spray , , ...
... Offers One Stop for Market-Specific Managed Care Enrollment ... and Health Plan Trends , , NASHVILLE, ... managed care market intelligence, reports that commercial pharmacy ... the state level than commercial medical benefit enrollment. ...
... solid reputation within industry , , HOFFMAN ESTATES, ... Spine, Inc. announced today that it has appointed Todd P. ... Fanning has held senior sales and marketing positions at well ... orthopaedic industries, including Spinal Concepts (now part of Zimmer ...
... Selected as Best EHR/PM System to Help Physicians, Organization ... , , DALLAS, June 9 ... software solutions for physician practices, announced today that after ... Physicians, Organization of the University Medical Center ...
... Cyrus at the 20th Annual A Time For Heroes Family ... AIDS Foundation , , LOS ANGELES, June 9 ... 20th annual A Time For Heroes Family Picnic, held June ... Pediatric AIDS Foundation. More than 80 of Hollywood,s best-known names ...
... Kennedy On Some Points, Denise Gott Agrees that Everyone ... Acute Ones , , KIRKLAND, Wash., June 9 ... terms with a Democratic Congress on health reform, according ... praise on Senator Edward Kennedy (D-MA) for his crusading ...
Cached Medicine News:Health News:Par Pharmaceutical Begins Shipment of Generic Miacalcin(R) 2Health News:Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment 2Health News:The Physicians' Organization of the University Medical Center at Princeton Chooses iMedica's EHR and Practice Management Solutions 2Health News:The Physicians' Organization of the University Medical Center at Princeton Chooses iMedica's EHR and Practice Management Solutions 3Health News:Celebrities Come Together to Fight Pediatric AIDS 2Health News:Celebrities Come Together to Fight Pediatric AIDS 3Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 2Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 3Health News:Insurance Leader Praises Senator Kennedy for Promoting Long-Term Care Aid for All Americans as Part of Health Reform 4
... catheter is a coaxial, ... is made of PEBAX ... in the inner balloon ... markings enhance the visibility ...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
Medicine Products: